Assessment of Lab4P Probiotic Effects on Cognition in 3xTg-AD Alzheimer's Disease Model Mice and the SH-SY5Y Neuronal Cell Line
Aging and metabolic syndrome are associated with neurodegenerative pathologies including Alzheimer's disease (AD) and there is growing interest in the prophylactic potential of probiotic bacteria in this area. In this study, we assessed the neuroprotective potential of the Lab4P probiotic consortium in both age and metabolically challenged 3xTg-AD mice and in human SH-SY5Y cell culture models of neurodegeneration. In mice, supplementation prevented disease-associated deteriorations in novel object recognition, hippocampal neurone spine density (particularly thin spines) and mRNA expression in hippocampal tissue implying an anti-inflammatory impact of the probiotic, more notably in the metabolically challenged setting. In differentiated human SH-SY5Y neurones challenged with β-Amyloid, probiotic metabolites elicited a neuroprotective capability. Taken together, the results highlight Lab4P as a potential neuroprotective agent and provide compelling support for additional studies in animal models of other neurodegenerative conditions and human studies.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
International journal of molecular sciences - 24(2023), 5 vom: 28. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Webberley, Thomas S [VerfasserIn] |
---|
Links: |
---|
Themen: |
Alzheimer’s disease |
---|
Anmerkungen: |
Date Completed 14.03.2023 Date Revised 14.03.2023 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/ijms24054683 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM354077481 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM354077481 | ||
003 | DE-627 | ||
005 | 20231226061438.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/ijms24054683 |2 doi | |
028 | 5 | 2 | |a pubmed24n1180.xml |
035 | |a (DE-627)NLM354077481 | ||
035 | |a (NLM)36902113 | ||
035 | |a (PII)4683 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Webberley, Thomas S |e verfasserin |4 aut | |
245 | 1 | 0 | |a Assessment of Lab4P Probiotic Effects on Cognition in 3xTg-AD Alzheimer's Disease Model Mice and the SH-SY5Y Neuronal Cell Line |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.03.2023 | ||
500 | |a Date Revised 14.03.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Aging and metabolic syndrome are associated with neurodegenerative pathologies including Alzheimer's disease (AD) and there is growing interest in the prophylactic potential of probiotic bacteria in this area. In this study, we assessed the neuroprotective potential of the Lab4P probiotic consortium in both age and metabolically challenged 3xTg-AD mice and in human SH-SY5Y cell culture models of neurodegeneration. In mice, supplementation prevented disease-associated deteriorations in novel object recognition, hippocampal neurone spine density (particularly thin spines) and mRNA expression in hippocampal tissue implying an anti-inflammatory impact of the probiotic, more notably in the metabolically challenged setting. In differentiated human SH-SY5Y neurones challenged with β-Amyloid, probiotic metabolites elicited a neuroprotective capability. Taken together, the results highlight Lab4P as a potential neuroprotective agent and provide compelling support for additional studies in animal models of other neurodegenerative conditions and human studies | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Alzheimer’s disease | |
650 | 4 | |a cognition | |
650 | 4 | |a neurodegeneration | |
650 | 4 | |a probiotics | |
650 | 7 | |a tau Proteins |2 NLM | |
650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
700 | 1 | |a Bevan, Ryan J |e verfasserin |4 aut | |
700 | 1 | |a Kerry-Smith, Joshua |e verfasserin |4 aut | |
700 | 1 | |a Dally, Jordanna |e verfasserin |4 aut | |
700 | 1 | |a Michael, Daryn R |e verfasserin |4 aut | |
700 | 1 | |a Thomas, Sophie |e verfasserin |4 aut | |
700 | 1 | |a Rees, Meg |e verfasserin |4 aut | |
700 | 1 | |a Morgan, James E |e verfasserin |4 aut | |
700 | 1 | |a Marchesi, Julian R |e verfasserin |4 aut | |
700 | 1 | |a Good, Mark A |e verfasserin |4 aut | |
700 | 1 | |a Plummer, Sue F |e verfasserin |4 aut | |
700 | 1 | |a Wang, Duolao |e verfasserin |4 aut | |
700 | 1 | |a Hughes, Timothy R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 24(2023), 5 vom: 28. Feb. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2023 |g number:5 |g day:28 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms24054683 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 24 |j 2023 |e 5 |b 28 |c 02 |